These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 35343648)

  • 1. Quality of life in patients with locally advanced head and neck squamous cell carcinoma undergoing concurrent chemoradiation with once-a-week versus once-every-3-weeks cisplatin.
    Menon NS; Noronha V; Patil VM; Joshi A; Bhattacharjee A; Kalra D; Laskar SG; Mathrudev V; Nawale K; Bhelekar AS; Prabhash K
    Cancer Med; 2022 Nov; 11(21):3939-3948. PubMed ID: 35343648
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life in patients with locally advanced head and neck cancer treated with concurrent chemoradiation with cisplatin and nimotuzumab versus cisplatin alone - Additional data from a phase 3 trial.
    Menon N; Patil V; Noronha V; Joshi A; Bhattacharjee A; Satam BJ; Mathrudev V; Ghosh Laskar S; Prabhash K
    Oral Oncol; 2021 Nov; 122():105517. PubMed ID: 34560383
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Once-a-Week Versus Once-Every-3-Weeks Cisplatin Chemoradiation for Locally Advanced Head and Neck Cancer: A Phase III Randomized Noninferiority Trial.
    Noronha V; Joshi A; Patil VM; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; D'Cruz AK; Banavali S; Pai PS; Chaturvedi P; Chaukar D; Pande N; Chandrasekharan A; Talreja V; Vallathol DH; Mathrudev V; Manjrekar A; Maske K; Bhelekar AS; Nawale K; Kannan S; Gota V; Bhattacharjee A; Kane S; Juvekar SL; Prabhash K
    J Clin Oncol; 2018 Apr; 36(11):1064-1072. PubMed ID: 29220295
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial.
    Harrington KJ; Ferris RL; Blumenschein G; Colevas AD; Fayette J; Licitra L; Kasper S; Even C; Vokes EE; Worden F; Saba NF; Kiyota N; Haddad R; Tahara M; Grünwald V; Shaw JW; Monga M; Lynch M; Taylor F; DeRosa M; Morrissey L; Cocks K; Gillison ML; Guigay J
    Lancet Oncol; 2017 Aug; 18(8):1104-1115. PubMed ID: 28651929
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab.
    Curran D; Giralt J; Harari PM; Ang KK; Cohen RB; Kies MS; Jassem J; Baselga J; Rowinsky EK; Amellal N; Comte S; Bonner JA
    J Clin Oncol; 2007 Jun; 25(16):2191-7. PubMed ID: 17538164
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-Term Update of a Phase 3 Randomized Study Comparing Once-a-Week Versus Once-Every-3-Weeks Cisplatin Along With Radiation in Head and Neck Cancer.
    Noronha V; Patil V; Menon N; Singh A; Shah M; Shetake A; Peelay Z; Mathrudev V; Nawale K; Shah S; Prabhash K
    Int J Radiat Oncol Biol Phys; 2025 Jan; 121(1):128-136. PubMed ID: 39074566
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin, and Docetaxel within the CEFCID Trial.
    Goerling U; Gauler T; Dietz A; Grünwald V; Knipping S; Guntinas-Lichius O; Frickhofen N; Lindeman HW; Fietkau R; Haxel B; Große-Thie C; Maschmeyer G; Zipfel M; Martus P; Knoedler M; Keilholz U; Klinghammer K
    Oncol Res Treat; 2022; 45(6):319-325. PubMed ID: 34915492
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Health-related quality of life in patients with metastatic, relapsed, or inoperable squamous cell carcinoma of the head and neck in India.
    Noronha V; Joshi A; Marfatia S; Patil V; Juvekar S; Arya S; Banavali S; Prabhash K
    Support Care Cancer; 2016 Apr; 24(4):1595-602. PubMed ID: 26386707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality of life and swallowing with standard chemoradiotherapy versus accelerated radiotherapy and panitumumab in locoregionally advanced carcinoma of the head and neck: A phase III randomised trial from the Canadian Cancer Trials Group (HN.6).
    Ringash J; Waldron JN; Siu LL; Martino R; Winquist E; Wright JR; Nabid A; Hay JH; Hammond A; Sultanem K; Hotte S; Leong C; El-Gayed AA; Naz F; Ramchandar K; Owen TE; Montenegro A; O'Sullivan B; Chen BE; Parulekar WR
    Eur J Cancer; 2017 Feb; 72():192-199. PubMed ID: 28040660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase 3 trial comparing nimotuzumab plus cisplatin chemoradiotherapy versus cisplatin chemoradiotherapy alone in locally advanced head and neck cancer.
    Patil VM; Noronha V; Joshi A; Agarwal J; Ghosh-Laskar S; Budrukkar A; Murthy V; Gupta T; Mahimkar M; Juvekar S; Arya S; Mahajan A; Agarwal A; Purandare N; Rangarajan V; Balaji A; Chaudhari SV; Banavali S; Kannan S; Bhattacharjee A; D'Cruz AK; Chaturvedi P; Pai PS; Chaukar D; Pantvaidya G; Nair D; Nair S; Deshmukh A; Thiagarajan S; Mathrudev V; Manjrekar A; Dhumal S; Maske K; Bhelekar AS; Nawale K; Chandrasekharan A; Pande N; Goel A; Talreja V; Simha V; Srinivas S; Swami R; Vallathol DH; Dsouza H; Shrirangwar S; Turkar S; Abraham G; Thanky AH; Patel U; Pandey MK; Prabhash K
    Cancer; 2019 Sep; 125(18):3184-3197. PubMed ID: 31150120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality of life of patients with locally advanced head and neck cancer treated with induction chemotherapy followed by cisplatin-containing chemoradiotherapy in the Dutch CONDOR study: a randomized controlled trial.
    Driessen CML; Groenewoud JMM; de Boer JP; Gelderblom H; van der Graaf WTA; Prins JB; Kaanders JHAM; van Herpen CML
    Support Care Cancer; 2018 Apr; 26(4):1233-1242. PubMed ID: 29230548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cisplatin Weekly Versus Every 3 Weeks Concurrently with Radiotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinomas: What Is the Best Dosing and Schedule?
    Mashhour K; Hashem W
    Asian Pac J Cancer Prev; 2020 Mar; 21(3):799-807. PubMed ID: 32212810
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Standard Radiation Versus Accelerated Radiation Plus Cisplatin for Locally Advanced Head and Neck Carcinoma: NRG Oncology RTOG 0129.
    Xiao C; Zhang Q; Nguyen-Tân PF; List M; Weber RS; Ang KK; Rosenthal D; Filion EJ; Kim H; Silverman C; Raben A; Galloway T; Fortin A; Gore E; Winquist E; Jones CU; Robinson W; Raben D; Le QT; Bruner D
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):667-677. PubMed ID: 27727063
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quality of life of patients receiving platinum-based chemotherapy plus cetuximab first line for recurrent and/or metastatic squamous cell carcinoma of the head and neck.
    Mesía R; Rivera F; Kawecki A; Rottey S; Hitt R; Kienzer H; Cupissol D; De Raucourt D; Benasso M; Koralewski P; Delord JP; Bokemeyer C; Curran D; Gross A; Vermorken JB
    Ann Oncol; 2010 Oct; 21(10):1967-1973. PubMed ID: 20335368
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Quality of Life and Performance Status From a Substudy Conducted Within a Prospective Phase 3 Randomized Trial of Concurrent Accelerated Radiation Plus Cisplatin With or Without Cetuximab for Locally Advanced Head and Neck Carcinoma: NRG Oncology Radiation Therapy Oncology Group 0522.
    Truong MT; Zhang Q; Rosenthal DI; List M; Axelrod R; Sherman E; Weber R; Nguyen-Tân PF; El-Naggar A; Konski A; Galvin J; Schwartz D; Trotti A; Silverman C; Singh A; Godette K; Bonner JA; Jones CU; Garden AS; Shenouda G; Matthiesen C; Le QT; Bruner D
    Int J Radiat Oncol Biol Phys; 2017 Mar; 97(4):687-699. PubMed ID: 27727066
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Short-term health-related quality of life and symptom control with docetaxel, cisplatin, 5-fluorouracil and cisplatin (TPF), 5-fluorouracil (PF) for induction in unresectable locoregionally advanced head and neck cancer patients (EORTC 24971/TAX 323).
    van Herpen CM; Mauer ME; Mesia R; Degardin M; Jelic S; Coens C; Betka J; Bernier J; Remenar E; Stewart JS; Preiss JH; van den Weyngaert D; Bottomley A; Vermorken JB;
    Br J Cancer; 2010 Oct; 103(8):1173-81. PubMed ID: 20842129
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Single-Arm Phase 2 Trial of Elective Nodal Dose Reduction for Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.
    Maguire PD; Neal CR; Hardy SM; Schreiber AM
    Int J Radiat Oncol Biol Phys; 2018 Apr; 100(5):1210-1216. PubMed ID: 29452770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase II/III Randomized Controlled Trial of Concomitant Hyperfractionated Radiotherapy plus Cetuximab (Anti-EGFR Antibody) or Chemotherapy in Locally Advanced Head and Neck Cancer.
    Al-Saleh K; El-Sherify M; Safwat R; Elbasmy A; Shete J; Hussein A; Nazeeh M; Bedair A
    Gulf J Oncolog; 2019 May; 1(30):6-12. PubMed ID: 31242976
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Quality of life of locally advanced cervical cancer patients after neoadjuvant chemotherapy followed by chemoradiation versus chemoradiation alone (CIRCE trial): a randomized phase II trial.
    Nunes de Arruda F; da Costa S; Bonadio R; Dornellas A; Pereira D; de Bock GH; Del Pilar Estevez Diz M
    Int J Gynecol Cancer; 2020 Jun; 30(6):749-756. PubMed ID: 32321767
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial.
    Paccagnella A; Favaretto A; Oniga F; Barbieri F; Ceresoli G; Torri W; Villa E; Verusio C; Cetto GL; Santo A; De Pangher V; Artioli F; Cacciani GC; Parodi G; Soresi F; Ghi MG; Morabito A; Biason R; Giusto M; Mosconi P; Chiarion Sileni V;
    Lung Cancer; 2004 Jan; 43(1):83-91. PubMed ID: 14698542
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.